Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Type 2 Diabetes Mellitus: Update Bulletin [December 2017]

Product Code:
596200940
Publication Date:
December 2017
Format:
PDF
Price:
£910

Gain new key opinion leader (KOL) insights on the latest events happening in T2DM. Topics covered include; expert views on Novo Nordisk’s recently approved once-weekly GLP-1 agonist, semaglutide (Ozempic); opinions on the results of the Phase IIIb/IV EXSCEL study which is assessing the cardiovascular (CV) risk of AstraZeneca’s Bydureon (exenatide extended release) in T2DM patients; and views on Zafgen’s ZGN-1061, a fumagillin-class, injectable small molecule second generation MetAP2 inhibitor, which recently entered Phase II clinical development.

Business Questions:

• Do KOLs perceive semaglutide to have any advantages over other once-weekly GLP-1 agonists?
• What is KOL perception of semaglutide’s safety profile?
• Where do experts see this semaglutide fitting into the treatment algorithm?
• How do KOLs view the results of the EXSCEL study and will it impact prescribing of Bydureon?
• Do KOLs raise any new safety concerns based on the findings of the EXSCEL study?
• What strategies do experts suggest for growing Bydureon’s market share?
• How do KOLs perceive ZGN-1061’s mechanism of action?
• How do KOLs view ZGN-1061’s subcutaneous mode of delivery?
• Where do KOLs see ZGN-1061 fitting into the T2DM treatment algorithm?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved